BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
24 Abril 2023 - 7:45AM
MAINZ, Germany, April 24,
2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX,
“BioNTech” or “the Company”) will announce its financial results
for the first quarter 2023 on Monday, May 8th, 2023. BioNTech
invites investors and the general public to join a conference call
and webcast with investment analysts on the same day at 8.00 a.m.
EDT (2.00 p.m. CEST) to report its financial results and provide a
corporate update for the first quarter 2023.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a pin will be provided. It is recommended to register
at least a day in advance.
The slide presentation and audio of the webcast
will be available via this link.
Participants may also access the slides and the
webcast of the conference call via the “Events & Presentations”
page of the Investor Relations section of the Company’s website at
www.BioNTech.com. A replay of the webcast will be available shortly
after the conclusion of the call and archived on the Company’s
website for 30 days following the call.
About BioNTech Biopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
immune checkpoint modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron,
Genevant, Fosun Pharma, and Pfizer.
For more information, please visit
www.BioNTech.com.
BioNTech Contacts
Investor RelationsVictoria Meissner,
M.D.+1 617 528 8293Investors@biontech.de
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
